CN Patent

CN116211796A — 一种立他司特滴眼液及其制备方法

Assigned to New Leading Chongqing Pharmaceutical Technology Co ltd · Expires 2023-06-06 · 3y expired

What this patent protects

本发明属于药物制剂技术领域，涉及一种立他司特滴眼液及其制备方法，单剂量制剂包括以下组分：立他司特5％～10％，渗透压调节剂1％～3％、缓冲剂0.1％～0.3％、pH调节剂及注射用水。本发明不含抗氧剂以及抑菌剂，制备的制剂杂质水平优于含抗氧剂的处方，因此该处方工艺可提高制剂的安全性，且适用于工业生产。

USPTO Abstract

本发明属于药物制剂技术领域，涉及一种立他司特滴眼液及其制备方法，单剂量制剂包括以下组分：立他司特5％～10％，渗透压调节剂1％～3％、缓冲剂0.1％～0.3％、pH调节剂及注射用水。本发明不含抗氧剂以及抑菌剂，制备的制剂杂质水平优于含抗氧剂的处方，因此该处方工艺可提高制剂的安全性，且适用于工业生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN116211796A
Jurisdiction
CN
Classification
—
Expires
2023-06-06
Drug substance claim
No
Drug product claim
No
Assignee
New Leading Chongqing Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.